![]() ![]() Neither greenfield projects, further acquisitions nor synergies with HELIOS are included in the 2017 projections. Key drivers of the anticipated EBITDA growth are already implemented synergy projects related to the 2014 merger of IDC and GHQ, recent acquisitions, well-advanced efficiency projects as well as operating leverage. The purchase price corresponds to approximately 10.8x at the mid-point of the 2017 EBITDA range. In 2017, EBITDA is expected to be in the range of €520 to €550 million. Going forward, cross-selling between the recently acquired ORPs and Quirónsalud’s hospitals are expected to be yet another growth driver.įor 2016, Quirónsalud expects sales of approximately €2.5 billion and EBITDA of €460 to €480 million. Greenfield hospital projects and acquisitions have also contributed to Quirónsalud’s overall strong sales growth. ![]() Under the PPP agreements, Quirónsalud is assigned responsibility for the publicly insured inhabitants of certain coverage areas and receives remuneration based on capitation or activity performed. Quirónsalud is also a pioneer in public-private partnership (“PPP”) models, operating five hospitals (four in Madrid and one in Barcelona) that are integrated within the public healthcare network. Growth is driven by an above-market increase of patient admissions due to excellent quality of care combined with consistently short waiting times. Quirónsalud has posted organic sales growth of more than 5% p.a. Quirónsalud was created by the merger of IDC Salud (“IDC”) and Grupo Hospitalario Quirón (“GHQ”) in 2014. The company has about 35,000 employees and offers the full spectrum of inpatient and outpatient care. Quirónsalud’s network is comprised of 43 hospitals, 39 outpatient centers and around 300 Occupational Risk Prevention (“ORP”) centers located in all economically important areas in Spain. (“Quirónsalud”), Spain’s largest private hospital operator, for a purchase price of €5.76 billion 2. Highly accretive to Group earnings per share from 2017įresenius Helios acquires IDC Salud Holding S.L.U.Substantial growth opportunities and cost synergies.Mutual best-practice transfer to further enhance quality patient care in both markets, creating a European leader in hospital management.Adds 43 hospitals across Spain and sales of approximately €2.5 billion 1 to HELIOS’ leading German network.From a local pharmacy to a global corporation.This superhero fights for healthy kidneys.‘Sometimes we understand each other without words’.Rehabilitation, Care and Health Tourism. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |